From Pasteur to genomics: Progress and challenges in infectious diseases

Nature Medicine

Volumn 10, Issue 11, 2004, Pages 1177-1185

  Rappuoli, Rino ^a  

^a CHIRON VACCINES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMANTADINE; ANTIRETROVIRUS AGENT; ENFUVIRTIDE; HUMAN MONOCLONAL ANTIBODY; INACTIVATED VACCINE; LAMIVUDINE; LIVE VACCINE; MENINGOCOCCUS VACCINE; MONOCLONAL ANTIBODY; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RECOMBINANT DNA; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SMALL INTERFERING RNA; SMALLPOX VACCINE; VACCINE; VIRUS PROTEIN; VIRUS VACCINE; ZIDOVUDINE;

ANTHRAX; ANTIBIOTIC RESISTANCE; AVIAN INFLUENZA; BACTERIAL MENINGITIS; BACTERIAL SPORE; BIOLOGICAL WARFARE; BLOOD TRANSFUSION; BOVINE SPONGIFORM ENCEPHALOPATHY; CLINICAL TRIAL; CREUTZFELDT JAKOB DISEASE; DRUG APPROVAL; DRUG COST; EPIDEMIC; FLAVIVIRUS; GENE SEQUENCE; GENOMICS; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INFECTION PREVENTION; INFLUENZA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR CLONING; NUCLEIC ACID AMPLIFICATION; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; STREPTOCOCCUS INFECTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; COMMUNICABLE DISEASES, EMERGING; GENOMICS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; VACCINES; WORLD HEALTH;

ANTHRAX; AVES; BACTERIA (MICROORGANISMS); BOVINAE; CORONAVIRUS; FLAVIVIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; SARS CORONAVIRUS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; VARIOLA VIRUS;

EID: 9144229137     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1129     Document Type: Review

References (65)

1. McNeill, W.H. Plagues and peoples, 365 (Anchor Books, New York, 1998).
2. Roberts, L. Polio. Health workers scramble to contain African epidemic. Science 305, 24-25 (2004).
3. Flannery, B. et al. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA 291, 2197-2203 (2004).
4. Costantino, P. et al. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 10, 691-698 (1992).
5. Ramsay, M.E., Andrews, N., Kaczmarski, E.B. & Miller, E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England, Lancet 357, 195-196 (2001).
6. Trotter, C.L., Andrews, N.J., Kaczmarski, E.B., Miller, E. & Ramsay, M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364, 365-367 (2004).
7. Choo, Q.L. et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359-362 (1989).
8. Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300 (1997).
9. Markina, S.S., Maksimova, N.M., Vitek, C.R., Bogatyreva, E.Y. & Monisov, A.A. Diphtheria in the Russian Federation in the 1990s. J. Infect. Dis. 181, S27-S34 (2000).
10. Sack, D.A., Sack, R.B., Nair, G.B. & Siddique, A.K. Cholera. Lancet 363, 223-233 (2004).
11. Normile, D. & Enserink, M. Infectious diseases. Avian influenza makes a comeback, reviving pandemic worries. Science 305, 321 (2004).
12. Guan, Y. et al. H5N1 influenza: a protean pandemic threat. Proc. Natl. Acad. Sci. USA 101, 8156-3161 (2004).
13. Li, K.S. et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430, 209-213 (2004).
14. Stadler, K. et al. SARS-beginning to understand a new virus. Nat. Rev. Microbiol. 1, 209-218 (2003).
15. Leroy, E.M. et al. Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science 303, 387-390 (2004).
16. Lowy, F.D. Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Invest. 111, 1265-1273 (2003).
17. Schmidt, F.R. The challenge of multidrug resistance: actual strategies in the development of novel antibacterials. Appl. Microbiol. Biotechnol. 63, 335-343 (2004).
18. Reacher, M.H. et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ 320, 213-216 (2000).
19. Cooper, B.S. et al. Methicillin-resistant Staphylococcus aureus in hospitals and the community: stealth dynamics and control catastrophes. Proc. Natl. Acad. Sci. USA 101, 10223-10228 (2004).
20. Morens, D.M., Folkers, G.K. & Fauci, A.S. The challenge of emerging and re-emerging infectious diseases. Nature 430, 242-249 (2004).
21. Fleischmann, R.D. et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269, 496-512 (1995).
22. Relman, D.A., Schmidt, T.M., MacDermott, R.P. & Falkow, S. Identification of the uncultured bacillus of Whipple's disease. N. Engl. J. Med. 327, 293-301 (1992).
23. Relman, D.A. The search for unrecognized pathogens. Science 284, 1308-1310 (1999).
24. Houghton, M. & Abrignani, S. Vaccination against the hepatitis C viruses, in New Generation Vaccines (eds Levine, M.M., Kaper, J.B., Rappuoli, R., Liu, M.A., Good, M.F.) 593-606 (Marcel Dekker, Inc., New York, 2004).
25. Bisht, H. et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. USA 101, 6641-6646 (2004).
26. Traggiai, E. et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10, 871-875 (2004).
27. Hamelin, M.E., Abed, Y. & Boivin, G. Human metapneumovirus: a new player among respiratory viruses. Clin. Infect. Dis. 38, 983-990 (2004).
28. McDaniel, T.K. & Valdivia, R.H. Promising new tools for virulence gene discovery, in Cellular Microbiology (eds Cossart, P., Boquet, P., Normark, S., Rappuoli, R.) 333-345 (ASM Press, Washington DC, 2000).
29. Cossart, P., Boquet, P., Normark, S. & Rappuoli, R. Cellular microbiology emerging. Science 271, 315-316 (1996).
30. Cornells, G.R. & Van Gijsegem, F. Assembly and function of type III secretory systems. Annu. Rev. Microbiol. 54, 735-774 (2000).
31. Cascales, E. & Christie, P.J. The versatile bacterial type IV secretion systems. Nat. Rev. Microbiol. 1, 137-149 (2003).
32. Clifford, R.J. et al. Bioinformatics tools for single nucleotide polymorphism discovery and analysis. Ann. NY Acad. Sci. 1020, 101-109 (2004).
33. Bleharski, J.R. et al. Use of genetic profiling in leprosy to discriminate clinical forms of the disease. Science 301, 1527-1530 (2003).
34. Mueller, A. et al. Protective immunity against Helicobacter is characterized by a unique transcriptional signature. Proc. Natl. Acad. Sci. USA 100, 12289-12294 (2003).
35. Rappuoli, R. Reverse vaccinology. Curr. Opin. Microbiol. 3, 445-450 (2000).
36. Koutsky, L.A. et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645-1651 (2002).
37. Mora, M., Veggi, D., Santini, L., Pizza, M. & Rappuoli, R. Reverse vaccinology. Drug Discov. Today 8, 459-464 (2003).
38. Shiver, J.W. et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335 (2002).
39. Shiver, J.W. & Emini, E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med. 55, 355-372 (2004).
40. McConkey, S.J. et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9, 729-735 (2003).
41. Sullivan, N.J. et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424, 681-684 (2003).
42. Athman, R. & Philpott, D. Innate immunity via Toll-like receptors and Nod proteins. Curr. Opin. Microbiol. 7, 25-32 (2004).
43. Krieg, A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760 (2002).
44. Field, H.J., De Clercq, E. Antiviral drugs - a short history of their discovery and development. Microbiology Today 31, 58-61 (2004).
45. De Clercq, E. Strategies in the design of antiviral drugs. Nat. Rev. Drug Discov. 1, 13-25 (2002).
46. Matthews, T. et al. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov. 3, 215-225 (2004).
47. Howard, K. Unlocking the money-making potential of RNAi. Nat. Biotechnol. 21, 1441-1446 (2003).
48. Behring, E.A. & Kitasato, S. Ueber das Zustandekommen der diphtherie-immunitat und dertetanus-immunitat bei thieren. Deuten Med Woch 49, 1113-1114 (1890).
49. Johnson, S. et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176, 1215-1224 (1997).
50. Casadevall, A., Dadachova, E., Pirofski, L. Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol. 2, 695-703 (2004).
51. Busch, M.P., Kleinman, S.H. & Nemo, G.J. Current and emerging infectious risks of blood transfusions. JAMA 289, 959-962 (2003).
52. Stramer, S.L. et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N. Engl. J. Med. 351, 760-768 (2004).
53. Venter, J.C. et al. Environmental genome shotgun sequencing of the Sargasso Sea, Science 304, 66-74 (2004).
54. Walters, M.J. Six Modern Plagues, 19-46 (Island Press, Washington, 2003).
55. Guan, Y. et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302, 276-278 (2003).
56. Minor, P.D. Polio eradication, cessation of vaccination and re-emergence of disease. Nat. Rev. Microbiol. 2, 473-482 (2004).
57. Bloom, B.R. & Murray, C.J. Tuberculosis: commentary on a reemergent killer. Science 257, 1055-1064 (1992).
58. Gostin, L.O. International infectious disease law: revision of the World Health Organization's International Health Regulations. JAMA 291, 2623-2627 (2004).
59. Harris, D.A. (ed.) Mad cow disease and related spongiform encephalopathies, 219 (Springer-Verlag, Berlin, 2004).
60. Giles, J. Tissue survey raises spectre of 'second wave'of vCJD. Nature 429, 331 (2004).
61. McHutchison, J.G. Understanding hepatitis C. Am. J. Manag. Care 10, S21-S9 (2004).
62. Roig, J., Sabria, M. & Pedro-Botet, M.L. Legionella spp.: community acquired and nosocomial infections. Curr. Opin. Infect. Dis. 16, 145-151 (2003).
63. Steinbrook, R. The AIDS epidemic in 2004. N. Engl. J. Med. 351, 115-117 (2004).
64. Granwehr, B.P. et al. West Nile virus: where are we now? Lancet Infect. Dis. 4, 547-556 (2004).
65. Levy, S.B. Antibiotic resistance: consequences of inaction. Clin. Infect. Dis. 33, S124-S129 (2001).